Equillium Inc (NAS:EQ)
$ 1.5594 0.0194 (1.26%) Market Cap: 54.98 Mil Enterprise Value: 22.73 Mil PE Ratio: 0 PB Ratio: 2.60 GF Score: 34/100

Equillium Inc at Leerink Partners Global Healthcare Conference Transcript

Feb 28, 2019 / 03:00PM GMT
Release Date Price: $7.87 (+3.28%)
Pasha Sarraf
Leerink Partners LLC - Analyst

All right, good morning, everybody. I'm Pasha Sarraf with Leerink and I'm delighted to host Bruce Steel and Steve Connelly from Equillium. Bruce is the President and Chief Business Officer; and Steve is the Chief Scientific Officer. Equillium is a very exciting company and they've just recently had an announcement around their -- the indications that they've chosen.

So, let's get started by first talking about sort of what the announcement was, the indications you're going after and then I'd like to get into the biology.

Bruce Steel
Equillium, Inc. - President & Chief Business Officer

Okay, excellent. Well, thank you, Pasha, and thank you everybody for attending and hearing a little bit about the Equillium story. We're very pleased to be here today.

So, the announcement that we provided on Tuesday was our first update since our public offering which was completed in October. And we announced primarily two things; one is the addition of lupus nephritis as our next clinical indication that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot